Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CTSK | P43235 | 11/20 | 0.62 |
| ▸ | CTSS | P25774 | 3/20 | 0.58 |
| ▸ | CTSL | P07711 | 3/20 | 0.58 |
| ▸ | CTSB | P07858 | 2/20 | 0.58 |
| ▸ | CTRB1 | P17538 | 2/20 | 0.58 |
| ▸ | PSMB1 | P20618 | 1/20 | 0.56 |
| ▸ | PSMB5 | P28074 | 1/20 | 0.56 |
| ▸ | PSMB2 | P49721 | 1/20 | 0.56 |
| ▸ | ATM | Q13315 | 1/20 | 0.54 |
| ▸ | CAPN1 | P07384 | 1/20 | 0.54 |
| ▸ | CAPN2 | P17655 | 1/20 | 0.54 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5724608 | 1.00 | CTSK (0.62) | CTSKCTSSCTSLCTSBCTRB1 | |
| SCHEMBL14923444 | 1.00 | CTSK (0.62) | CTSKCTSSCTSLCTSBCTRB1 | |
| SCHEMBL8971948 | 0.90 | CTSK (0.72) | CTSKCTSSCTSLCTSBPSMB1 | |
| SCHEMBL10983417 | 0.89 | CTSK (0.60) | CTSKCTSSCTSLCTSBCTRB1 | |
| SCHEMBL10983415 | 0.89 | CTSK (0.60) | CTSKCTSSCTSLCTSBCTRB1 | |
| SCHEMBL14595271 | 0.89 | CTSK (0.64) | CTSKCTSSCTSLCTSBCTRB1 | |
| SCHEMBL13074183 | 0.89 | CTSK (0.64) | CTSKCTSSCTSLCTSBCTRB1 | |
| SCHEMBL4829896 | 0.88 | CTRB1 (0.68) | CTSKCTSSCTSLCTSBCTRB1 | |
| SCHEMBL25182274 | 0.87 | CTSK (0.61) | CTSKCTSSCTSLCTSBCTRB1 | |
| SCHEMBL2724462 | 0.87 | CTSK (0.61) | CTSKCTSSCTSLCTSBCTRB1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 136 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3191098-A1 | COMBINATIONS AND DOSING REGIMES TO TREAT RB-POSITIVE TUMORS | G1 Therapeutics, Inc. (US) | 2017-07-19 | — | — | EP | claimed |
| WO-2016040858-A1 | COMBINATIONS AND DOSING REGIMES TO TREAT RB-POSITIVE TUMORS | G1 THERAPEUTICS, INC. (US) | 2016-03-17 | — | — | WO | claimed |
| EP-2968290-A1 | TRANSIENT PROTECTION OF NORMAL CELLS DURING CHEMOTHERAPY | G1 Therapeutics, Inc. (US) | 2016-01-20 | — | — | EP | claimed |
| WO-2015161285-A1 | TRICYCLIC LACTAMS FOR USE IN THE PROTECTION OF HEMATOPOIETIC STEM AND PROGENITOR CELLS AGAINST IONIZING RADIATION | G1 THERAPEUTICS, INC. (US) | 2015-10-22 | — | — | WO | claimed |
| WO-2015161288-A1 | TRICYCLIC LACTAMS FOR USE AS ANTI-NEOPLASTIC AND ANTI-PROLIFERATIVE AGENTS | G1 THERAPEUTICS, INC. (US) | 2015-10-22 | — | — | WO | claimed |
| WO-2015161287-A1 | TRICYCLIC LACTAMS FOR USE IN THE PROTECTION OF NORMAL CELLS DURING CHEMOTHERAPY | G1 THERAPEUTICS, INC. (US) | 2015-10-22 | — | — | WO | claimed |
| WO-2014144326-A1 | TRANSIENT PROTECTION OF NORMAL CELLS DURING CHEMOTHERAPY | G1 THERAPEUTICS, INC. (US) | 2014-09-18 | — | — | WO | claimed |
| EP-2632467-A1 | CDK INHIBITORS | G1 Therapeutics, Inc. (US) | 2013-09-04 | — | — | EP | claimed |
| WO-2012061156-A1 | CDK INHIBITORS | TAVARES FRANCIS X (US) | 2012-05-10 | — | — | WO | claimed |
| EP-4596051-A2 | HSPC-SPARING TREATMENTS FOR RB-POSITIVE ABNORMAL CELLULAR PROLIFERATION | Pharmacosmos Holding A/s (DK) | 2025-08-06 | — | — | EP | disclosed |
| US-12285431-B2 | Treatment of Rb-negative tumors using topoisomerase inhibitors in combination with cyclin dependent kinase 4/6 inhibitors | PHARMACOSMOS HOLDING A/S (DK) | 2025-04-29 | — | — | US | disclosed |
| EP-2968291-B1 | HSPC-SPARING TREATMENTS FOR RB-POSITIVE ABNORMAL CELLULAR PROLIFERATION | PHARMACOSMOS HOLDING AS (DK) | 2025-04-16 | — | — | EP | disclosed |
| US-12110308-B2 | Phosphor(n)amidatacetal and phosph(on)atalcetal compounds | NUCORION PHARMACEUTICALS, INC. (US) | 2024-10-08 | — | — | US | disclosed |
| US-20240109906-A1 | CDK INHIBITORS | G1 THERAPEUTICS, INC. (US) | 2024-04-04 | — | — | US | disclosed |
| US-5654467-A | Process for the production of C-substituted diethylenetriamines | SCHERING AKTIENGESELLSCHAFT (DE) | 1997-08-05 | — | — | US | disclosed |
| EP-0680464-B1 | DERIVATED DTPA COMPLEXES, PHARMACEUTICALS CONTAINING THESE COMPOUNDS, THEIR USE AS NMR- AND RADIOGRAPHIC CONTRASTING AGENTS AND PROCESS FOR PRODUCING THE SAME | SCHERING AG (DE) | 1997-04-09 | — | — | EP | disclosed |
| EP-0680464-A1 | DERIVATED DTPA COMPLEXES, PHARMACEUTICALS CONTAINING THESE COMPOUNDS, THEIR USE AS NMR- AND RADIOGRAPHIC CONTRASTING AGENTS AND PROCESS FOR PRODUCING THE SAME. | SCHERING AG (DE) | 1995-11-08 | — | — | EP | disclosed |
| EP-0680467-A1 | PROCESS FOR PREPARING C-SUBSTITUTED DIETHYLENE TRIAMINES | SCHERING AKTIENGESELLSCHAFT (DE) | 1995-11-08 | — | — | EP | disclosed |
| WO-1994017029-A1 | DERIVATED DTPA COMPLEXES, PHARMACEUTICALS CONTAINING THESE COMPOUNDS, THEIR USE AS NMR- AND RADIOGRAPHIC CONTRASTING AGENTS AND PROCESS FOR PRODUCING THE SAME | SCHERING AKTIENGESELLSCHAFT (DE) | 1994-08-04 | — | — | WO | disclosed |
| WO-1994017033-A1 | PROCESS FOR PREPARING C-SUBSTITUTED DIETHYLENE TRIAMINES | SCHERING AKTIENGESELLSCHAFT (DE) | 1994-08-04 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240109906-A1 | CDK INHIBITORS | CDK3, CDK9, CDK6 | CTSK 1426/4885CTSS 2527/4885CTSL 2084/4885 |
| US-12285431-B2 | Treatment of Rb-negative tumors using topoisomerase inhibitors in combination with cyclin dependent kinase 4/6 inhibitors | RB1, CDK4, CDK6 | CTSK 2201/4885CTSS 3037/4885CTSL 2542/4885 |
| US-12110308-B2 | Phosphor(n)amidatacetal and phosph(on)atalcetal compounds | PYGL, MTMR1, PTEN | CTSK 2473/4885CTSS 2988/4885CTSL 1746/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.